Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourStrong Bullish
15 minStrong Bearish
5 minExpanding
Daily trend turns up above $23.56
Key levels
Resistance$20.73
Resistance$18.56
Support$16.32
Support$14.38
Latest news & SEC filings
SEC FilingBeta Bionics, Inc. filed an insider trading report (Form 4)
All BBNX news →Beta Bionics makes devices for people who need insulin to manage diabetes. Its main offering is the iLet Bionic Pancreas, an automated insulin delivery system cleared for Type 1 diabetes patients aged six and up, which pairs with continuous glucose monitors and uses adaptive algorithms to set insulin doses. The company sells across the United States via its own sales, clinical, and support teams, focusing on endocrinology practices and later primary care, with reimbursement through durable medical equipment and pharmacy benefit channels. It is also working on a tubeless patch pump and a bihormonal insulin-and-glucagon system.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
SEPT Low Target
$11.00
SEPT Mid Target
$22.50
SEPT High Target
$30.00
Analyst Consensus
$22.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BBNX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$22.41
42
Moat Score
NARROW
5/9
Piotroski Score
8.3
Altman Z-Score
Insider Signal
SELLING
0 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Hopman Mark | officer | Sale | 370 | $6K | Nov 2, 2026 |
| Mensinger Mike | officer | Sale | 2,650 | $58K | Oct 27, 2026 |
| Hopman Mark | officer | Sale | 821 | $16K | Oct 26, 2026 |
| Hopman Mark | officer | Sale | 775 | $13K | Oct 14, 2026 |
| Hopman Mark | officer | Sale | 370 | $7K | Oct 1, 2026 |
| Jones Christy | director | Sale | 6,430 | $148K | Sep 22, 2026 |
| Hopman Mark | officer | Sale | 36,870 | $681K | Sep 9, 2026 |
| Hopman Mark | officer | Sale | 35,994 | $665K | Sep 9, 2026 |
| Saint Sean | director officer | Sale | 5,641 | $113K | Sep 3, 2026 |
| Hopman Mark | officer | Sale | 275 | $3K | Jun 4, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
53.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
78.95%
FCF Growth YoY
-8.8%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for BBNX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:33:02 | $17.12 | 1,000 | $$17K | BUY |
| 18:03:03 | $17.52 | 7,000 | $$123K | MIDPOINT |
| 17:56:02 | $17.38 | 1,230 | $$21K | BUY |
| 16:22:57 | $16.73 | 2,800 | $$47K | BUY |
| 16:08:28 | $16.95 | 1,000 | $$17K | BUY |
5 dark pool trades shown · $$225K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Beta Bionics, Inc. (BBNX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Beta Bionics, Inc. (BBNX) is at $17.11, down 3.96% (-$0.70) at the Nov 12, 2026 close.
Latest BBNX news — Nov 9, 2026: Beta Bionics, Inc. filed an insider trading report (Form 4)
The average analyst price target for BBNX is $22.50, ranging from $11 to $30, based on 10 analysts. Latest: TD Cowen maintains on Oct 28, 2026.
Analyst ratings for BBNX: 0 Buy, 15 Hold, 0 Sell — consensus Hold.
BBNX last reported on Oct 27, 2026: EPS -$0.52 vs -$0.52 expected — a beat of 0.6%.
BBNX does not currently pay a dividend.
Support: $16.32, $14.38, $12.73. Resistance: $18.56, $20.73, $22.29.
Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.
Nov 9, 2026: Beta Bionics, Inc. filed an insider trading report (Form 4)